EGFR and laryngotracheoesophageal cleft: Adenocarcinoma is usually associated with activating mutations in the epidermal growth factor receptor (EGFR) gene and LC patients with activating mutations in the kinase domain of EGFR can be treated with tyrosine kinase inhibitors (TKIs) (Casás-Selves et al., 2012; Nakayama et al., 2014).